Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HJC0152 hydrochloride (HJC0152) 是一种信号转导和转录激活因子 3的抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 239 | 现货 | ||
2 mg | ¥ 336 | 现货 | ||
5 mg | ¥ 583 | 现货 | ||
10 mg | ¥ 919 | 现货 | ||
25 mg | ¥ 1,750 | 现货 | ||
50 mg | ¥ 2,580 | 现货 | ||
100 mg | ¥ 3,530 | 现货 | ||
200 mg | ¥ 4,970 | 现货 | ||
500 mg | ¥ 7,970 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 598 | 现货 |
产品描述 | HJC0152 hydrochloride (HJC0152) is a signal transducer and activator of transcription 3 (STAT3) inhibitor. |
体外活性 | HJC0152 inhibits STAT3 promoter activity in MDA-MB-231 cells in a dose-dependent manner. It has a comparable potency in downregulating STAT3 protein production and phosphorylation at the Tyr-705 site. HJC0152 induces cleaved caspase-3 and downregulated cyclin D1 in MDA-MB-231 cells, inhibits cell cycle progression and promotes apoptosis. HJC0152 treatment efficiently suppresses HNSCC cell proliferation, arrests the cell cycle at the G0/G1 phase, induces apoptosis, and reduced cell invasion in both SCC25 and CAL27 cell lines. Moreover, HJC0152 inhibits nuclear translocation of phosphorylated STAT3 at Tyr705 and decreases VHL/β-catenin signaling activity via regulation of microRNA-21. |
体内活性 | HJC0152 significantly suppresses MDA-MB-231 xenograft tumor growth in vivo (ip and po), indicating its great potential as efficacious and orally bioavailable therapeutics for human cancer. It has an improved oral bioavailability and an enhanced suppression of tumor growth in mice. HJC0152 does not show significant signs of toxicity at a dose of 75 mg/kg. In SCC25-derived orthotopic mouse models, HJC0152 treatment significantly abrogates STAT3/β-catenin expression in vivo, which leading to a global decrease of tumor growth and invasion. |
别名 | HJC0152 |
分子量 | 406.64 |
分子式 | C15H14Cl3N3O4 |
CAS No. | 1420290-99-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 82 mg/mL (201.7 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4592 mL | 12.2959 mL | 24.5918 mL | 61.4794 mL |
5 mM | 0.4918 mL | 2.4592 mL | 4.9184 mL | 12.2959 mL | |
10 mM | 0.2459 mL | 1.2296 mL | 2.4592 mL | 6.1479 mL | |
20 mM | 0.123 mL | 0.6148 mL | 1.2296 mL | 3.074 mL | |
50 mM | 0.0492 mL | 0.2459 mL | 0.4918 mL | 1.2296 mL | |
100 mM | 0.0246 mL | 0.123 mL | 0.2459 mL | 0.6148 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
HJC0152 hydrochloride 1420290-99-8 Apoptosis JAK/STAT signaling Stem Cells STAT Inhibitor HJC0152 Hydrochloride HJC-0152 HJC0152 HJC 0152 Hydrochloride HJC-0152 Hydrochloride inhibit HJC 0152 HJC-0152 hydrochloride inhibitor